Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharmaceuticals, Inc. - Common Stock (NQ:CPRX)

24.45 +0.08 (+0.33%)
Streaming Delayed Price Updated: 2:29 PM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Catalyst Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Relay Therapeutics Stock Shows Market Leadership With Jump To 94 RS Rating
Relay Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, with an upgrade from 84 to 94. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 24, 2022
  
Via Benzinga
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade
On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94. 
Via Investor's Business Daily
11 Health Care Stocks Moving In Wednesday's Pre-Market Session
  Gainers   
Via Benzinga
Piper Sandler Increases Catalyst Pharma's Price Target Slightly After Q4 Earnings
Via Benzinga
Catalyst Pharmaceuticals: Q2 Earnings Insights
  Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Catalyst Pharmaceuticals Shares Are Moving Today
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading lower by 1.47% at $10.71. Traders and investors are watching for the company’s second-quarter earnings report, confirmed for Tuesday’s... 
Via Benzinga
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
On Monday, Kura Oncology stock had its Relative Strength (RS) Rating upgraded to 91, up from 85 a day earlier. 
Via Investor's Business Daily
A Preview Of Catalyst Pharmaceuticals' Earnings
  Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. 
Via Benzinga
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET 
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
6 Best-Performing Robinhood Stocks Of 2022
The SPDR S&P 500 ETF Trust (NYSE: SPY) is off to a brutal start to 2022, down 12.1% year-to-date. Robinhood Markets Inc (NASDAQ: HOOD) has been one of the worst performers of all so far this year,... 
Via Benzinga
7 Smart Stocks to Buy Now Under $10
There are always good stocks to buy somewhere. What you should be focused on is finding the smart stocks that add value to your portfolio. 
Via InvestorPlace
This Coal Company's 1-Year Return Handily Beats Moderna, Catalyst Pharmaceuticals, Globalstar And Dogecoin
Alpha Metallurgical Resources Inc (NYSE:AMR) is known as a le... 
Via Benzinga
Catalyst Pharmaceuticals's Return On Capital Employed Insights
According to Benzinga Pro data Catalyst Pharmaceuticals (NASDAQ:CPRX) posted a 9.88% decrease in earnings from Q3. Sales, however, increased by 6.55% over the previous quarter to... 
Via Benzinga
Recap: Catalyst Pharmaceuticals Q4 Earnings
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported its Q4 earnings results on Wednesday, March 16, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Earnings Scheduled For March 16, 2022
Companies Reporting Before The Bell • Ideanomics (NASDAQ:IDEX) is likely to report quarterly loss at $0.05 per share on revenue of $33.20 million. • Tarena... 
Via Benzinga
Earnings Preview For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ:CPRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-16. Here's what investors need to know before the announcement.... 
Via Benzinga
Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity
Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) anticipates  
Via Benzinga
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments... 
Via Benzinga
7 of the Top-Rated Pharmaceutical Stocks for Q1
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. 
Via InvestorPlace
The Top 3 Robinhood Stocks of 2021
The Robinhood trading platform is controversial, but it has drawn investors to many stocks that have posted big gains in the last year. 
Via InvestorPlace
47 Biggest Movers From Yesterday
Gainers Nuvectis Pharma, Inc. (NASDAQ: NVCT) shares surged 144.6% to close at $7.95 on Monday. The company, on Friday, priced its IPO at $5 per share. Anghami Inc. (NASDAQ: ANGH... 
Via Benzinga
If You Invested $1,000 In Catalyst Pharmaceuticals Stock One Year Ago, Here's How Much You'd Have Now
Investors who have owned stocks in the last year have generally experienced some big gains. In fact, the SPDR S&P 500 ETF Trust (NYSE: SPY) total return over the last 12... 
Via Benzinga
Topics Stocks
Exposures US Equities
Catalyst Pharmaceuticals, inc (CPRX) Q3 2021 Earnings Call Transcript
CPRX earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
3 Low-Priced Stocks That Make Smart Bets
There are still plenty of low-priced stocks that would make great additions to your portfolio and have the potential for higher gains. 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS